Repare Therapeutics Inc. ("Repare") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform ...

Financial Guidance Based on its current operating plan, Arvinas believes its cash, cash equivalents, and marketable securities as of March 31, 2025, is sufficient to fund planned operating expenses ...

Materion Corporation (NYSE: MTRN) today reported first quarter 2025 financial results and provided an update to the full year ...